Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.DARE · Entity 7799 | Chief Commercial Officer | March 12, 2024 | March 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date March 12, 2024 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2034-03-12 | Direct | 290,000 |
Reported balance
After 2024-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-12 · Grant · Acquired 290,000 · Balance 290,000 F1: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2024 Filed Mar 14, 2024 20:39 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 290,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001401914-24-000008 · wk-form4_1710448743.xml · derivative · entry 1 Fair John A · CIK 0001739140 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,000 Underlying: Common stock · 290,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 290,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001401914-23-000006 · wf-form4_167476712040761.xml · derivative · entry 1 Fair John A · CIK 0001739140 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common stock · 290,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 21:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001401914-22-000009 · wf-form4_164340390259574.xml · derivative · entry 1 Fair John A · CIK 0001739140 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common stock · 185,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:17 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 168,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001739140-21-000002 · wf-form4_161186864677254.xml · derivative · entry 1 Fair John A · CIK 0001739140 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common stock · 168,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:47 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantEmployee Stock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001401914-20-000036 · wf-form4_158379045238597.xml · derivative · entry 1 Fair John A · CIK 0001739140 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common stock · 68,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.